Cipher Pharmaceuticals (TSE:CPH) Reaches New 1-Year High – Still a Buy?

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares reached a new 52-week high on Wednesday . The company traded as high as C$17.37 and last traded at C$17.24, with a volume of 28602 shares trading hands. The stock had previously closed at C$16.85.

Cipher Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 4.36, a quick ratio of 2.67 and a current ratio of 1.12. The stock has a market cap of C$433.32 million, a price-to-earnings ratio of 16.27 and a beta of 1.33. The business’s fifty day simple moving average is C$14.98 and its 200 day simple moving average is C$14.94.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.